An article in the November issue of the American Journal of Medicine reports that a study of almost 400,000 COPD and asthma patients showed a 34% increase in the rate of Type 2 diabetes among those using inhaled corticosteroid (ICS). Higher doses of ICS were associated with higher increased risk of developing diabetes. The study was conducted by researchers from the Lady Davis Institute for Medical Research at Jewish General Hospital in Montreal, Canada. Read the abstract.
